Cargando…
Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate
PURPOSE: Intravenously (i.v.) administered nanomedicines have the potential for tumour targeting due to the enhanced permeability and retention (EPR) effect, but in vivo tumour models are rarely calibrated with respect to functional vascular permeability and/or mechanisms controlling intratumoural d...
Autores principales: | Duncan, Ruth, Sat-Klopsch, Yee-Nee, Burger, Angelika M., Bibby, Michael C., Fiebig, Heinz H., Sausville, Edward A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718995/ https://www.ncbi.nlm.nih.gov/pubmed/23797686 http://dx.doi.org/10.1007/s00280-013-2209-7 |
Ejemplares similares
-
Augmentation of EPR Effect and Efficacy of Anticancer Nanomedicine by Carbon Monoxide Generating Agents
por: Fang, Jun, et al.
Publicado: (2019) -
Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control
por: Shen, Yao An, et al.
Publicado: (2015) -
Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control [Corrigendum]
Publicado: (2017) -
Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery
por: Dhaliwal, Alexander, et al.
Publicado: (2019) -
Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors
por: Kim, Jinseong, et al.
Publicado: (2023)